Gw Research Limited

Gw Pharma Limited

Jazz Pharmaceuticals Research UK Limited

Otsuka Pharmaceutical Company, Limited

International Standard Electric Corporation

Stc, Inc

Compass Pathfinder Limited

Standard Telephones and Cables Public Limited Company

Stephen Wright

Geoffrey W Guy

Orrin Devinsky

Alice Mead

Daniela Parolaro

Tetsuro Kikuchi

Marie Woolley-Roberts

James Brodie

Livio Luongo

Julian Scott Northen

David E Nichols

Derek John Londesbrough

Hemant Kashinath Patil

Christopher Brown

Gillian Moore

Colin Stott

Vincenzo Di Marzo

Ekaterina Malievskaia

George Goldsmith

Lars Christian Wilde

Manon Cecile Elisabeth Veraart

Rafael Maldonado

Jitinder Wilkhu

Tobias Patrick Whelan

Hans Åke Eriksson

Lindsey Marwood

Shaun Hurley

Megan Croal

Molly Tabitha Hickey

Drummond E-Wen Joe McCulloch

Laurie Emma Medhurst

Nathan Poulsen

Aslihan Selimbeyoglu

Anaïs Soula

Amanda Tan Shuxiang

Angelo Antonio Izzo

Elizabeth Thiele

Richard E Epworth

Angus Dalgleish

Claire Williams

Gary Stephens

Wai Liu

Luciano De Petrocellis

Alan Sutton

Sofia Torres

Etienne De Meijer

Mar Lorente

Katherine Scott

Sharon Anavi-Goffer

David Potter

Charuta Joshi

Angus Wilfong

Paola Massi

Francesca Borrelli

Gabriella Aviello

Aniello Schiano Moriello

Ruth Alexandra Ross

Lesley Ann Ford

Manuel Guzman

Guillermo Velasco

Alessia Ligresti

Terry Bricheno

Benjamin Whalley

Melvin M Ramsay

Philip R Couch

Philip Robson

Roger J Brambley

Ben Whalley

Anne Comi

David F Smith

Joanna Neill

Anthony W Davis

Emma Cheetham

Dominic Schiller

Teresa Iuvone

Francesca Borelli

Cristina Sanchez

Maria Munoz Caffarel

Clara Andradas

Harpreet Singh

Eduardo PÉREZ GÓMEZ

Michael Cawthorne

The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Use of cannabinoids in the treatment of epilepsy

The present invention relates to the use of a combination of two different cannabinoids in the treatment of leukaemia. The combination of CBD with THC appears to be particularly effective in reducing cell number in this disease. Preferably the cannabinoids are used in the form of an extract ofsuch that many of the naturally occurring compounds are co-extracted with the THC or CBD. Alternatively, the cannabinoids are present in the form of a highly purified extract of, wherein the CBD or THC are present at greater than 98% of the total extract (w/w) and the other components of the extract are characterized. Alternatively, the CBD and THC may be synthetically produced. A specific ratio of CBD and THC such as 10:1 to 1:10 (CBD:THC) or more preferably between 2:1 to 1:2 (CBD:THC) may be used.

Combination of cannabinoids in the treatment of leukemia

The present invention relates to the use of cannabidiolic acid (CBDA) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders, such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). CBDA has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS and AS. The CBDA is preferably substantially pure. It may take the form of a highly purified extract ofsuch that the CBDA is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDA is synthetically produced.

Use of cannabidiolic acid in the treatment of autism spectrum disorder and associated disorders

The present invention relates to parenteral cannabinoid formulations, and more particularly to cannabinoid containing intravenous (IV) formulations. Preferably the parenteral containing formulation comprises a cannabinoid; an isotonic agent; a surfactant; and one or more stability enhancers. Furthermore the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).

Parenteral formulations

The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of 'treatment-resistant epilepsy' (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a further embodiment the invention relates to the use of CBDV in the treatment of schizophrenia. CBDV has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS, AS and schizophrenia. The CBDV is preferably substantially pure. It may take the form of a highly purified extract ofsuch that the CBDV is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDV is synthetically produced.

Use of cannabidivarin in the treatment of autism spectrum disorder, associated disorders and schizophrenia

The present invention relates to the use of cannabidiol (CBD) in the treatment of Angelman syndrome (AS). CBD has been shown to be particularly effective in improving anxiety in rodent models of AS. The CBD is preferably substantially pure. It may take the form of a highly purified extract ofsuch that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBD is synthetically produced. Alternatively, the CBD may be used as a botanical drug substance (BDS) from aplant in which CBD is the predominant cannabinoid. The CBD may also be present in combination with other cannabinoids and non-cannabinoid components such as terpenes. In use the CBD may be used concomitantly with one or more other medicaments. Alternatively, the CBD may be formulated for administration separately, sequentially or simultaneously with one or more medicaments or the combination may be provided in a single dosage form. Where the CBD is formulated for administration separately, sequentially or simultaneously it may be provided as a kit or together with instructions to administer the one or more components in the manner indicated. It may also be used as the sole medication, i.e. as a monotherapy.

Use of cannabinoids in the treatment of Angelman syndrome

Growing community of inventors

London, United Kingdom

Stephen Wright